KYMR Kymera Therapeutics
- 46.470
- +0.300+0.65%
- 46.470
- 0.0000.00%
Kymera Therapeutics News
Kymera Therapeutics Analyst Ratings
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $56
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Guggenheim Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $52
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $53 to $60
Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating
Leerink Partners Maintains Kymera Therapeutics(KYMR.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $56
Kymera Therapeutics Analyst Ratings
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Raises Target Price to $60
Leerink Partners Initiates Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $60
Wolfe Research Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Announces Target Price $65
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $45
Kymera Therapeutics Analyst Ratings
Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $45
Balancing Pipeline Potential and Clinical Risks: Kymera Therapeutics' Strategic Update and Hold Rating
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Kymera Therapeutics (KYMR) and Viridian Therapeutics (VRDN)
Kymera Therapeutics Analyst Ratings
Analysis
Price Target
No Data
No Data